Artios Pharma collected $115 million from an oversubscribed series D that will support its growing ambitions for its pipeline ...

Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential ...

How luxury doomsday bunkers turned into a billionaire status symbol ...

The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.